Stock Update: Actavis plc (NYSE:ACT) – Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin)

[PR Newswire] – DUBLIN, March 2, 2015 /PRNewswire/– Actavis plc (ACT) today announced that the European Commission has granted Actavis’ subsidiary Durata Therapeutics International B.V., marketing authorization for XYDALBA™ (dalbavancin) for the treatment . . . → Read More: Stock Update: Actavis plc (NYSE:ACT) – Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin) Similar Articles: Company Update (NYSE:ACT): (OFFICIAL)-UPDATE 1-Actavis’ superbug antibiotic gets U.S. approval (Feb. 25) Stock Update: BB&T Corporation (NYSE:BBT) – BB&T receives approval for Texas branch acquisition Stock Update (NYSE:ACE): ACE Aviation reports third quarter results and provides an update on its liquidation process
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.